Form 4 for JAZZ Jazz Pharmaceuticals plc
Accepted 2025-03-03 00:00:00 ET · period of report 2025-02-27 · accession 0001765581-25-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-03 | 2025-02-27 | JAZZ | Carr Patricia | SVP, CAO | M - OptEx | $113.77 | +4,813 | 8,550 | +129% | +$547.6K |
| DM | 2025-03-03 | 2025-02-27+ | JAZZ | Carr Patricia | SVP, CAO | S - Sale+OE | $144.27 | -5,586 | 9,485 | -37% | -$805.9K |
| DM | 2025-03-03 | 2025-02-27 | JAZZ | Carr Patricia | SVP, CAO | D - Sale to Iss | $142.43 | -868 | 7,369 | -11% | -$123.6K |
| D | 2025-03-03 | 2025-02-27 | JAZZ | Carr Patricia | SVP, CAO | A - Grant | $0.00 | +2,889 | 10.3K | +39% | $0 |
| DM | 2025-03-03 | 2025-02-27 | JAZZ | Carr Patricia | SVP, CAO | M - OptEx | $0.00 | -4,813 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-02-27 | M | A | 4,500 | $113.10 | 12,737 | D | — | — | |
| 2 | Common | Ordinary Shares | 2025-02-27 | S | D | 4,500 | $144.42 | 8,237 | D | — | — | |
| 3 | Common | Ordinary Shares | 2025-02-27 | M | A | 313 | $123.36 | 8,550 | D | — | — | |
| 4 | Common | Ordinary Shares | 2025-02-27 | S | D | 313 | $144.42 | 8,237 | D | — | — | |
| 5 | Common | Ordinary Shares | 2025-02-27 | D | D | 371 | $142.43 | 7,866 | D | — | — | |
| 6 | Common | Ordinary Shares | 2025-02-27 | D | D | 497 | $142.43 | 7,369 | D | — | — | |
| 7 | Common | Ordinary Shares | 2025-02-27 | A | A | 2,889 | $0.00 | 10,258 | D | — | — | |
| 8 | Common | Ordinary Shares | 2025-02-28 | S | D | 773 | $143.30 | 9,485 | D | — | — | |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-02-27 | M | D | 4,500 | $0.00 | 0 | D | $113.10 · — to 2030-02-26 | 4,500 Ordinary Shares | (F3) These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The options were fully vested as of the date of exercise. |
| 10 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-02-27 | M | D | 313 | $0.00 | 0 | D | $123.36 · — to 2026-02-24 | 313 Ordinary Shares | (F4) These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 25, 2016, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The options were fully vested as of the date of exercise. |